Flavonoid-powered therapy is a developing but also intricate area of oncologic intervention, provided that one must navigate through the regulatory structures that remain until now. The chapter outlines the regulatory paradigms that were used by the Food and Drug Administration (FDA), European Medicines Agency (EMA), and the World Health Organization (WHO) concerning these botanically derived compounds. Flavonoids are a type of polyphenol in plants, which have a potential anticancer effect through an array of activities, including antioxidant effect, induction of apoptosis, and alteration of immune responses, thereby affecting important signaling pathways through which cancer develops. However, issues such as variability in phenotypic source, limited bioavailability, and complexity of intellectual property provide significant impediments to development and approval. The FDA is highly evidence-based with a strict approach, but the EMA offers alternative routes to consider the traditional use of medicines, and the WHO attempts to promote global harmonization. Addressing these hurdles requires tactical interventions that would involve the development of innovative delivery models, uniformity in production procedures, and stringent clinical testing. The future of developments requires international collaboration and regulatory systems that will balance strict scientific attention with the unique characteristics of the natural product, thus ensuring innovation and preservation of patients’ safety and availability of flavonoid-derived anticancer treatments.